Kornimate/medical-research-clean huggingface dataset:
myoglobin removal by high cut-off cvvhd

Conditions: Rhabdomyolysis; Renal Failure

Summary: a high cut-off dialyzer (septex) is tested for the removal of myoglobin which is not efficiently removed by standard high flux dialysis membranes. hypothesis: the high cut-off dialyzer (septex) can remove 2-fold more efficiently myoglobin from the circulation of rhabdomyolysis patients as by conventional treatment with standard high flux dialyzer.

excess myoglobin in the circulation is a causative pathogenetic factor of rhabdomyolysis associated with acute kidney injury (aki). the rapid elimination of myoglobin by standard dialysis membranes is limited to its molecular weight of 17.8kda, although some removal can be achieved when a convective therapy is applied. significant clearance for myoglobin has been reported for high flux membranes from \< 8 ml/min (5) up to 22 ml/h (cvvh) (10) and for high cut-off (hco) membranes a mean clearance rate of 36.2 ml/min in hd mode (7) and 39.2 ml/h in cvvh mode (5). the use of high cut-off (hco) continuous veno- venous hemodialysis (cvvhd) may constitute a novel therapeutic strategy for effectively reduction of myoglobin in the patient's serum to ameliorate the course of aki. previously, a case study of the removal of myoglobin by hco-cvvh in one single patient with severe rhabdomyolysis was published.

Eligibility criteria:
inclusion criteria: * acute rhabdomyolysis * placed central venous catheter * indication for rrt due to serum ck level \> 5000 u/l * age ≥ 18 years * signed icf exclusion criteria: * end stage ckd (dialysis dependent) renal failure before manifestation of rhabdomyolysis * pregnancy or lactation * palliative treatment * participation in other clinical studies

Keywords: septex cvvh cvhd myoglobin
multiple breath nitrogen washout in healthy and cystic fibrosis adults

Conditions: Cystic Fibrosis; Healthy

Summary: this study compares the lung clearance index (lci) in cystic fibrosis and healthy adults obtained with two different multiple breath nitrogen washout (mbwn2) devices. each participants will perform the test (lci) in duplicate on each device.

using nitrogen as the inert gas, there are currently two commercially available devices that offer the possibility to measure the lci. however, comparison between them are lacking. the 2 mbwn2 devices are the "easyone pro lab" (ndd medical technologies, zürich, switzerland) and the "exhalyzer d" (eco medics ag, duernten, switzerland).

Eligibility criteria:
inclusion criteria: * cystic fibrosis diagnosis exclusion criteria: * respiratory infection within 3 weeks * chronically infected with methicillin-resistant staphylococcus aureus or burkholderia cepacia

Keywords: lung clearance index cystic fibrosis multiple breath nitrogen washout
brief, behavioral intervention to reduce douching among adolescent and young women

Conditions: Vaginal Douching; Bacterial Vaginosis

Summary: this study will implement and test a brief, tailored individual-level intervention to be used in two new orleans adolescent clinics with female patients aged 16-24 who douche.

the study implements a client-centered behavioral intervention (ccbi) based on prochaska's transtheoretical model of change (tmc) and the intervention will use miller's motivational interviewing (mi) techniques. this intervention will be evaluated using (1) an audio/computer-assisted self-administered interview (acasi) survey to assess changes in respondents' douching knowledge, attitudes, and practices, and (2) biological testing for bacterial vaginosis.

Eligibility criteria:
inclusion criteria: * women attending between the ages of 16 and 24 who have douched at least once in the last 180 days, agree to a test for bacterial vaginosis, and agree to allow us to contact you by telephone or in person for a follow-up interview and testing for bacterial vaginosis. exclusion criteria: * currently pregnant, non-english speaking
evaluating the revised worq in ci users

Conditions: Hearing Loss

Summary: the work related questionnaire (worq) is a 59-item questionnaire of which each item represents an international classification of functioning and disability category. the worq was modified and reduced to include only questions relevant to cochlear implant (ci) users. in this analysis, a multicentre retrospective review of the revised worq in ci users was performed, with the revised worq as part of the questionnaires used in the regular clinical follow-up of ci users. experienced ci users' responses on the questions will be evaluated to define the qualifiers for the revised worq.


Eligibility criteria:
inclusion criteria: * adults over the age of 18 years * adults must wear a med-el cochlear implant * adults may have the following hearing indications and device fitting: * unilateral cochlear implant with severe-to-profound hearing loss * bilateral cochlear implant with severe-to-profound hearing loss * single sided deafness (ssd) where the poorer ear pta ≥70 db hl and the better ear pta ≤30 db hl with an interaural threshold gap of ≥40 db hl. * asymmetrical hearing loss using a cochlear implant in the poorer ear and a hearing aid in the better ear (also known as bimodal fitting). the poorer ear pta ≥70 db hl and the better ear pta \>30 db hl and ≤55 db hl with an interaural threshold gap of ≥15 db hl. * adults should have a minimum of one year's device experience exclusion criteria no extra exclusion criteria

Keywords: work rehabilitation questionnaire international classification of functioning, disability and health cochlear implantation
epidemiology and control of mansonella perstans infection in uganda

Conditions: Mansonelliasis; Pruritus; Lymphoedema; Abdominal Pains

Summary: mansonella perstans (m. perstans) infection is widespread in uganda. knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. the study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of m. perstans infections in uganda.

overall objective: to investigate diagnostic, epidemiological and treatment aspects of m. perstans in uganda with relevance to control specific objectives: 1. to establish the pattern of diurnal periodicity of m. perstans microfilaraemia in humans 2. to establish the patterns of m. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity 3. to determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on m. perstans microfilaraemia.

Eligibility criteria:
inclusion criteria: * individuals \>= 5 years with or without m. perstans infection exclusion criteria: * individuals \< 5 years * pregnant women

Keywords: mansonella perstans microfilaraemia ivermectin albendazole uganda
effects of botulinum neurotoxin type a (bont/a) free of complexing proteins in the spastic equinovarus foot

Conditions: Stroke Rehabilitation; Stroke Rehabilitation Spasticity Management

Summary: clinical randomized clinical trial to assess the effectiveness on walking speed of repeated use of botulinum neurotoxin type a (bont/a)in the post-stroke spastic equinovarus foot in three successive infiltrations at 6-month intervals, checking if the sustainability of the effect is greater in incobotulinumtoxin a (xeomin®) than in onabotulinumtoxina (botox®).

spasticity is present in 38% of patients at six months after stroke. equinovarus foot, with or without claw toes and striatal foot, is especially common. there is a weak to moderate evidence in favor of the use of botulinum neurotoxin type a (bont/a) in the equinovarus foot, stiff-knee and in other patterns that may interfere with gait ability. specifically, bont/a increases walking speed in stroke patients with spastic equinovarus foot. repeated use of bont/a may lead to the appearance of neutralizing antibodies, so its effect may decrease over successive infiltrations. among the differential characteristics of incobotulinumtoxina (xeomin®) there is a reduced inactivated botulinum neurotoxin content and the lack of complexing proteins, which would diminish antigenicity and not suppose a decrease of the effect before successive infiltrations. the objective of this project is to determine the effect on walking speed of repeated use of bont/a in post-stroke spinal equinovarus foot in three consecutive injections at 6-month intervals and to investigate whether the sustainability of the effect is greater in incobotulinumtoxina (xeomin®) than in onabotulinumtoxina (botox®). all patients will receive 200-300 units of bont/a (xeomin ® or botox ®) that will be distributed according to the individual clinical pattern of spastic equinovarus foot.

Eligibility criteria:
inclusion criteria: * first-ever ischemic or haemorrhagic stroke * time since stroke onset: \>6months * hemiparesis with equinovarus foot * no previous bont/a exclusion criteria: * non-ambulant patients * medical contraindications for bont/a use that appear in the product information sheet

Keywords: walking disorder stroke botulinum toxin spasticity
exploring, predicting, and intervening on long-term viral suppression electronically

Conditions: HIV Infections

Summary: despite the widespread availability of effective antiretroviral therapy (art) in the united states, there remains significant numbers of people living with hiv (plwh) who fail to achieve and or maintain viral suppression (vs). disparities persist with the lowest levels of vs among black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to hiv care including racial discrimination, stigma and rural isolation.

this study will follow a digital cohort via the remain app. the remain app is adapted from the healthmpowerment (hmp) platform and tailored to our focus population's unique needs. digital cohorts, or ecohorts, utilize the flexibility and capacity of the internet to complement traditional approaches to epidemiological research, helping address some of the limitations and challenges associated with conventional cohort studies. aim 1 of this study is to recruit and retain a geographically and demographically diverse cohort of plwh who are sub optimally engaged in care and with a history of, at high risk for, or not currently virally suppressed. outcomes for this are levels of recruitment and retention to hit the study objectives to enroll 1,000 plwh at risk for or experiencing vns and follow them for up to 48 months. aim 2 is to evaluate longitudinal patterns of care engagement within the cohort by modeling and advanced epidemiologic methods utilizing remote collection of biomarkers of hiv disease (e.g., viral load), online surveys, and brief, frequent app-based "check-ins". outcomes include both those related to vs and engagement in care as well as engagement in the digital cohort.

Eligibility criteria:
inclusion criteria: * have access to a personal smartphone device; * over 18 years of age; * speak english or spanish; * living with hiv * are either 1) not currently virally suppressed, 2) not currently engaged in care, or 3) have one or more factors associated with viral non suppression including a history of missed appointments or viral non suppression; * active substance use or mental health disorder; * willing and able to provide written informed consent to take part in the study. exclusion criteria: * unwilling or unable to provide reliable contact information; * unwilling to provide blood sample for hiv virology testing; * living with hiv and virally suppressed and not at risk of becoming unsuppressed in the near future.
transmural collaborative care model for cvrm and medication review for patients using antipsychotics

Conditions: Mental Disorders, Severe

Summary: currently, monitoring of usage and effects of antipsychotic treatment and cardiovascular risk screening in patients with severe mental illness or antipsychotic treatment is not sufficient. a transmural collaborative care model for cardiovascular risk management and medication review for patients using atypical antipsychotics in general practice (tactic) was developed. this trial aims to assess the effectiveness of tactic regarding predicted cardiovascular risk and mental quality of life.

it is well established that patients with severe mental illness and patients treated with atypical antipsychotics have excess metabolic dysfunction and are at an increased risk of cardiovascular disease. currently, monitoring of usage and effects of antipsychotic treatment and cardiovascular risk screening in patients with severe mental illness or antipsychotic treatment is not sufficient. general practitioners experience barriers regarding knowledge, collaboration with psychiatrists, and patient compliance. to overcome these barriers a transmural collaborative care model for cardiovascular risk management and medication review for patients using atypical antipsychotics in general practice (tactic) was developed. tactic is a one-time transmural intervention comprising three steps: 1) an online information video to inform patients about the cardiovascular risks of antipsychotic use and the procedures of the multidisciplinary meeting, 2) a multidisciplinary meeting with the patient to review his or her antipsychotic use and cardiovascular risk and to provide tailored treatment advice, and 3) a follow-up contact with the general practitioner to translate the treatment advice into an individualised action plan through shared decision making. this trial aims to assess the effectiveness of tactic regarding predicted cardiovascular risk and mental quality of life.

Eligibility criteria:
inclusion criteria: * using atypical antipsychotic medication for at least 3 months at baseline * the atypical antipsychotic medication is prescribed by the general practitioner * a 10-year cardiovascular risk of at least 5% (as measured with qrisk3 score) at baseline exclusion criteria: * diagnosis of dementia or organic psychosis * diagnosis of cardiovascular disease (acute myocardial infarction, acute coronary syndrome, heart failure, ischemic stroke, transient ischemic attack, peripheral artery disease, aortic aneurysm or a revascularization procedure, i.e. percutaneous coronary intervention or coronary artery bypass grafting)

Keywords: primary health care antipsychotics cardiovascular risk collaborative care deprescribing off label
reduction of sweetened beverages and intrahepatic fat

Conditions: Obesity; Dyslipidemia; Metabolic Syndrome

Summary: the study will enroll 68 overweight male and female subjects with a high (\> 2 3dl-can soda/day) consumption of sweetened beverage per day. after a run-in period of 4 weeks, subjects will be randomized to either a 12-week intervention arm in which sweetened beverages will be replaced by artificially sweetened, calorie-free beverages, or to a control arm. the following measurements will be performed at the end of the run-in period and at the end of the intervention period * intrahepatic fat concentration * visceral fat volume * changes in day-long metabolic profile from baseline(plasma glucose, insulin, and triglyceride concentrations) * changes in food intake and daily energy, carbohydrate and sugars intake from baseline


Eligibility criteria:
inclusion criteria: * gender male or female * body mass index (bmi) \> 27 kg/m2 consumption of \> 2 3dl-can regular soda/day * low to moderate physical activity (\< 60 min walking/day; \< 3 exercise session/week exclusion criteria: * diabetes mellitus * liver, kidney or heart disease * any current drug treatment * contra-indications to mr examination (pacemaker, foreign bodies,etc) * pregnancy or planned pregnancy * active weight gain or weight loss (weight change \> 4 kg in the past 12 months) * consumption of drugs or illicit substances * consumption of more than 10g alcohol/day * vegetarians or subjects on special diets

Keywords: sugar sweetened beverages hepatic steatosis visceral obesity metabolic syndrome
test to stay in school: covid-19 testing following exposure in school communities

Conditions: Covid19

Summary: participants in school communities who have been exposed to sars-cov-2 will be tested for covid-19 on the day of exposure (day 1) and at days 3, 5, and 7 following initial known exposure. mitigation practices including masking, the context of exposure (classroom, school bus, after school sporting event, lunch, etc.), and results of covid-19 test will be documented.

this is a prospective, interventional study with a primary objective of evaluating severe acute respiratory syndrome coronavirus 2 (sars-cov-2) transmission following exposure in kindergarten through 12th grade schools. participants will be tested with a covid-19 testing kit that is food and drug administration (fda)-authorized under an emergency use authorization (eua) for non-prescription use for both symptomatic and asymptomatic evaluation in children and adults. participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known covid-19 exposure on day 0. if a participant does not know of the exposure until more than one day following they exposure, they will be tested on the day they become aware of the exposure and then resume the aforementioned testing schedule (e.g. participant identifies exposure 3 days after the exposure, test on day 3, day 5, and day 7). if the covid-19 tests are negative, the participant will remain in the school environment. a positive covid-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines. demographic information, daily presence or absence of symptoms, whether the infected person or close contact was masked, setting of the exposure, test results, and school absences will be collected following consent. data regarding school level mitigation practices will also be collected. data collected from this study may be combined with school-provided data and publically available community data.

Eligibility criteria:
inclusion criteria: * consent completed * child or adult that is part of a school community * known exposure to sars-cov-2 in the school setting (e.g. school bus, classroom, school sporting event, etc.) exclusion criteria: * none
evaluation of gadoterate in patients with decreased kidney function

Conditions: Renal Dysfunction

Summary: this study is for individuals with decreased kidney function whose doctor has ordered magnetic resonance imaging (mri). because kidney function is decreased, these patients usually do not receive the intravenous contrast material that can improve the accuracy of the mri findings. the purpose of this study is to evaluate the safety and benefit of using a contrast material called gadoterate in patients with decreased kidney function.

gadolinium-based intravenous contrast agents are widely used for the enhancement of mri findings. however, these agents have been implicated in varying degrees of nephrotoxicity and therefore are not usually used in patients with renal dysfunction. gadoterate is a gadolinium agent and previous studies have indicated that it is safe in patients with decreased kidney function. the purpose of this study is to evaluate the safety and efficacy of using gadoterate in this patient population. participants who have been scheduled for an mri will choose to either receive gadoterate contrast as part of their mri or not receive gadoterate as part of their mri.

Eligibility criteria:
inclusion criteria: * glomerular filtration rates (gfr) less than 30 ml/min but not on dialysis * being sent for an mri examination in the course of routine clinical evaluation of one of the following indications: suspected or known head/neck/brain mass, hepatic mass, renal mass, pancreatic mass, or prostate mass, as well as evaluation of carotid or abdominopelvic vasculature. exclusion criteria: * pregnant and lactating females * planned initiation of chemotherapy or surgery within 72 hours of the mri exam * hemodynamic instability or acute coronary syndrome * history of nephrotoxic medication within 2 weeks of the exam * less than 18 years old

Keywords: magnetic resonance imaging contrast agent gadoterate
innovating physical therapy: a pilot study on band connect's impact on compliance, satisfaction, and revenue

Conditions: Rotator Cuff Tears; Anatomic Total Shoulder Arthroplasty; Reverse Total Shoulder Arthroplasty

Summary: participants are being invited to take part in this research study because you will be undergoing total shoulder replacement or rotator cuff repair and will be participating in physical therapy rehabilitation following the procedure. the purpose of this research is to investigate the effectiveness of band connect, a connected health platform, in enhancing compliance with home exercise programs among patients undergoing physical therapy. this study aims to evaluate the implications of increased compliance on improving patient engagement and increasing satisfaction for both patients and clinicians. additionally, the study will analyze the economic implications of implementing band connect's hybrid care model on driving increased revenue per patient.


Eligibility criteria:
inclusion criteria: * age range: from 18 to 89 years old * surgery performed by dr. robert gillespie and will be undergoing post-op physical therapy rehabilitation at university hospitals * patients undergoing primary anatomic total shoulder shoulder arthroplasty (atsa) or primary reverse total shoulder arthroplasty (rtsa) * patients undergoing primary rotator cuff repair * prescribed outpatient physical therapy for post-operative rehabilitation chart review inclusion criteria: * age range: from 18 to 89 years old * surgery performed by dr. robert gillespie who underwent post-op physical therapy rehabilitation at university hospitals * patients who underwent primary anatomic total shoulder shoulder arthroplasty (atsa) or primary reverse total shoulder arthroplasty (rtsa) * patients who underwent primary rotator cuff repair * prescribed outpatient physical therapy for post-operative rehabilitation exclusion criteria: * patients undergoing hemiarthroplasty or revision tsa * patients undergoing revision rotator cuff repair * tsa performed for proximal humerus fractures * length of stay in hospital following shoulder surgery greater than 3 days * shoulder injuries related to workers compensation or involved in any pending litigation * pregnant individuals chart review exclusion criteria: * patients undergoing hemiarthroplasty or revision tsa * patients undergoing revision rotator cuff repair * tsa performed for proximal humerus fractures * length of stay in hospital following shoulder surgery greater than 3 days * shoulder injuries related to workers compensation or involved in any pending litigation * pregnant individuals

Keywords: physical therapy compliance home-based physical therapy
qualitative evaluation of tear fluid and blood for auto antibodies produced in response to covid-19

Conditions: SARS-CoV 2 Infection; Covid19

Summary: this study objective is to collect tear and blood samples from individuals with positive sars-cov2 diagnosis and test those samples for the presence of various sars-cov2 viral antigens and autoantibodies.


Eligibility criteria:
inclusion criteria: * 18 years of age or older has been tested for sars-cov2 and awaiting results sample collection for sars-cov2 testing tested positive for sars-cov2 virus (confirmed by rt-pcr) prior to enrollment exclusion criteria: * under 18 years of age concurrent eye infection or trauma unrelated to presence of sars-cov2 virus. advanced covid-19 state what would preclude safe and feasible sample collection.